MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Operating Income 2011-2026 | QTNT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -82.7 M | -80.4 M | -79.2 M | -70 M | -74.1 M | -49.1 M | -29.7 M | -8.89 M | -4.49 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.49 M | -82.7 M | -53.2 M |
Quarterly Operating Income Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.6 M | -89.1 M | -63.5 M | - | -31.3 M | -77 M | -45.7 M | -22 M | -21.6 M | -21.7 M | -13.1 M | -19.7 M | -22.4 M | -22.4 M | -18.4 M | -18.4 M | -19 M | -19 M | -21.1 M | - | -17.1 M | -18.1 M | -16.9 M | - | -22.4 M | -56.3 M | -33.9 M | - | -12.8 M | -36.2 M | -23.5 M | - | -7.33 M | -20 M | -12.6 M | - | -2.8 M | -4.29 M | -1.49 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.49 M | -89.1 M | -26 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
1.35 B | $ 118.25 | -1.27 % | $ 35.9 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 22.5 | 9.44 % | $ 242 M |  China |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 22.42 | 27.6 % | $ 1.19 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.46 | 2.82 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.56 | -0.24 % | $ 682 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 176.94 | -2.0 % | $ 8.77 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 515.65 | -0.56 % | $ 14.9 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 193.78 | -2.18 % | $ 138 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.16 | -5.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.24 | -1.91 % | $ 2 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 132.72 | 0.35 % | $ 21.1 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.13 | -0.25 % | $ 488 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.63 | -1.58 % | $ 20 B |  Niderland |
 |
Guardant Health
GH
|
-437 M | $ 85.7 | 0.99 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.83 | -3.41 % | $ 91.8 K | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.2 | 4.27 % | $ 5.05 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.77 | -1.88 % | $ 282 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 115.58 | -0.79 % | $ 9.53 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 266.36 | -0.14 % | $ 22.2 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.57 | - | $ 2.67 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Celcuity
CELC
|
-172 M | $ 125.25 | 1.44 % | $ 5.86 B | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 1.4 | 0.72 % | $ 92.3 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 5.0 | -3.66 % | $ 463 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 83.92 | -0.02 % | $ 5.66 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 516.0 | -2.95 % | $ 195 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.7 | -0.54 % | $ 61.9 M | Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 191.46 | 0.02 % | $ 21.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 5.17 | 0.58 % | $ 4.07 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 56.23 | -2.41 % | $ 3.36 B | USA |